Cipla Ltd has named chief operating officer Achin Gupta its next chief executive officer and managing director, succeeding Umang Vohra, who is exiting the pharma giant after a decade at the helm.

Cipla is betting big on its partnership with Eli Lilly to commercialize tirzepatide, the blockbuster diabetes and weight-loss drug sold globally under the brand name Mounjaro, as it seeks to deepen ...

Pharma major Cipla Ltd reported a steady performance for the second quarter ended September 30, 2025. Image Credit: Canva Cipla Share Price: Pharma major Cipla Ltd reported a steady performance for ...

Cipla Q2 FY26 Results: The India business generated Rs 3,146 crore in revenue, up 7 per cent YoY, led by solid traction in core therapies. Cipla’s respiratory brand Foracort retained its No. 1 ranking ...

Pharma major Cipla Ltd on Thursday reported a 3.7 per cent rise in consolidated net profit at ₹1,353.37 crore for the second quarter ended September 30, 2025. The company, which had posted a ...

Global CEO & MD Umang Vohra to step down in March end Global COO Achin Gupta to take over Cipla should focus on innovation over next 5-to-7 years - Vohra Beats second-quarter profit view Oct 30 ...

CHENNAI: India's fourth largest drug maker by revenue Cipla Ltd posted a steady performance for the September quarter, reporting a 4 percent year-on-year rise in consolidated net profit to Rs 1,351 ...

After nearly a decade at the helm, Umang Vohra is set to step down as the Managing Director and Global CEO of Cipla on March 31, 2026, marking the end of a transformative chapter in the 90-year-long ...

CHENNAI: Cipla Ltd on Thursday announced a planned leadership transition, with Managing Director and Global Chief Executive Officer Umang Vohra set to step down at the end of his current term in March ...

Pharmaceutical major Cipla is focusing on obesity and advanced diabetes care to maintain steady growth, as the revenue contribution from its key U.S. generic cancer drug, Revlimid, begins to slow. The ...

(Reuters) -Cipla's global chief executive and managing director, Umang Vohra, will step down at the end of March after almost a decade in the top role, the Indian drugmaker said on Thursday. Achin ...

Discover the best tablets under ₹30000 from top tablet brands. Tablets under ₹30,000 have become the go-to devices for those seeking a balance between performance, portability, and affordability.